Studie Combi I

Combi I

A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma

Study of safety and efficacy of PDR001 in combination with dabrafenib and trametinib in
patients with advanced melanoma

2016-002794-35

KUM - Klinik und Poliklinik für Dermatologie und Allergologie, München - Dermato-Onkologie

Interventionsstudie

Doppelt verblindet

III

Rekrutierung beendet

Positiv

Positiv

Unbekannt / Unbekannt

1

PDR001 in combination with dabrafenib and trametinib or placebo in combination with
dabrafenib and trametinib